<DOC>
	<DOC>NCT00436995</DOC>
	<brief_summary>The purpose of this study is to assess the proportion of subjects sucessfully achieving a mean Hemoglobin greater than or equal to 11 g/dL during the evaluation period following extension from Weekly (QW) to Once Every Other Week (Q2W) Darbepoetin Alfa administraion.</brief_summary>
	<brief_title>Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Receiving dialysis for 3 months or more before enrollment. The mean of 2 screening Hb values taken at least 7 days appart must be greater than or equal to 11g/dL and less than or equal to 13.0 g/dL Receiving stable QW darbepoetin alfa doses for at least 6 weeks before enrollment Adequate iron stores (serum ferritin equal to or greater than 100 ug/L Uncontrolled hypertension Prior history of Cardiovascular Incidents 12 weeks prior to enrollment Other hematological disorders Upper or lower GI bleed within the prior 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Anaemia</keyword>
</DOC>